Interstitial Lung Disease Trial, Recruiting NCT07484243 Sponsor: Dongyi He Condition: Interstitial Lung Disease
Back to Interstitial Lung Disease

Interstitial Lung Disease Trial, Recruiting

NCT07484243
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with rheumatoid arthritis (RA) based on recognised medical guidelines
  • You have a form of RA that has been difficult to treat and control, as defined by specific medical guidelines (confirm with trial site)
  • You have been jointly assessed by a joint specialist and a lung specialist, and have been diagnosed with a lung condition called interstitial lung disease (ILD) related to your RA, with other causes of lung scarring ruled out
  • Your RA and any related traditional Chinese medicine diagnosis has been assessed according to recognised Chinese medicine guidelines (confirm with trial site)
  • You are currently receiving traditional Chinese medicine as part of your treatment
  • You are 18 years old or older
  • You are willing and able to sign a consent form to take part in the study

Who may not be able to join:

  • You have a serious, worsening, or poorly managed condition affecting the kidneys, liver, blood, digestive system, hormones, lungs, heart, nerves, or mental health, or you currently have a known cancer
  • You have had significant known exposure to substances that can cause lung scarring, such as dust, asbestos, certain metals, radiation, or certain medications (confirm with trial site)
  • You have severe asthma or chronic obstructive pulmonary disease (COPD) that is not well controlled, and your medication for it has been changed in the last 3 months
  • You currently have an active infection that the research team believes could affect the study results
  • You have any other medical or test result findings that the research team considers significant enough to make participation unsuitable (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 15800300800

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Dongyi He
Registry
ClinicalTrials.gov
Start date
22 August 2025
Est. completion
30 September 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

DAS28-ESR at each time point

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov